I. Altintas

Low levels of the prognostic biomarker suPAR are predictive of mild outcome in patients with symptoms of COVID-19 - a prospective cohort study

H. Gamst-Jensen, L. Rasmussen, J. Nehlin, 2020, medRxiv.

Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

S. Loosen, F. Tacke, R. Pop-Busui, 2020, Journal of the American Society of Nephrology : JASN.

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19

S. Loosen, F. Tacke, R. Pop-Busui, 2022, Journal of the American Heart Association.

suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19

H. Gamst-Jensen, L. Rasmussen, J. Nehlin, 2021, Biomarker insights.

Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department

H. Gamst-Jensen, L. Rasmussen, J. Nehlin, 2021, The Journal of Emergency Medicine.

Appetite stimulation with cannabis‐based medicine and methods for assessment of glomerular filtration in older patients with medical illness: A study protocol

E. Porrini, J. A. Durhuus, M. Damgaard, 2023, Basic & clinical pharmacology & toxicology.

Biomarkers and the post-thrombotic syndrome: A systematic review of biomarkers associated with the occurrence of the post-thrombotic syndrome after lower extremity deep venous thrombosis

J. Nehlin, K. Iversen, O. Andersen, 2023, Phlebology.

Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.

M. Kretzler, E. Feldman, R. Pop-Busui, 2022, Diabetes care.